1. Home
  2. ATAT vs STVN Comparison

ATAT vs STVN Comparison

Compare ATAT & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atour Lifestyle Holdings Limited

ATAT

Atour Lifestyle Holdings Limited

HOLD

Current Price

$32.01

Market Cap

4.5B

ML Signal

HOLD

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

HOLD

Current Price

$17.53

Market Cap

3.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATAT
STVN
Founded
2013
1949
Country
China
Italy
Employees
N/A
N/A
Industry
Hotels/Resorts
Containers/Packaging
Sector
Consumer Discretionary
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
3.7B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
ATAT
STVN
Price
$32.01
$17.53
Analyst Decision
Strong Buy
Buy
Analyst Count
4
3
Target Price
$49.00
$25.67
AVG Volume (30 Days)
874.2K
364.2K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
2.06%
0.39%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$25.48
$9.67
Revenue Next Year
$18.11
$9.99
P/E Ratio
$26.11
$27.15
Revenue Growth
N/A
N/A
52 Week Low
$31.14
$12.89
52 Week High
$43.17
$28.00

Technical Indicators

Market Signals
Indicator
ATAT
STVN
Relative Strength Index (RSI) 38.96 50.76
Support Level N/A $16.75
Resistance Level $38.93 $19.41
Average True Range (ATR) 1.13 0.96
MACD -0.05 -0.01
Stochastic Oscillator 25.85 51.78

Price Performance

Historical Comparison
ATAT
STVN

About ATAT Atour Lifestyle Holdings Limited

Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.

Share on Social Networks: